Shire PLC



    Today's change

    26.00 / +0.56%

    1 year change


    As of Nov 27 2015 16:48 GMT. Data delayed by at least 15 minutes.

Search for Shire PLC and
  1. November 2, 2015

    Shire / Dyax: mother of pearls

    Flemming Ornskov, the chief executive of pharma group Shire, describes his acquisition strategy as a “string of pearls”...

  2. November 2, 2015

    Shire to buy US biotech group Dyax for $5.9bn

    Shire, the acquisitive London-listed drugmaker, has struck a defensive $5.9bn deal to buy Dyax, a US biotech company...

Special Reports

  1. Combating Rare Diseases

    For decades, rare diseases were all but ignored by the pharmaceuticals industry. That ...
Search more Special Reports on this topic.

  1. October 23, 2015

    Shire eyes alternatives amid pursuit of Baxalta

    Shire, the London-listed drugmaker, is still committed to its $30bn bid for Baxalta but the company is looking at other...

  2. October 19, 2015

    Anglo American slides on De Beers downturn fears

    Anglo American was Monday’s sharpest FTSE 100 faller on worries that its balance sheet strength will be tested by a...

  3. September 28, 2015

    Orphan drugs become big business

    Orphan drugs might target small groups of patients, but they are increasingly big business. Pharmaceutical companies,...

  4. August 21, 2015

    FTSE 100’s worst losing streak in four years

    Drugs manufacturer Shire led London’s main index lower on Friday, but its move into correction territory this week was...

  5. August 16, 2015

    Shire steps up pressure on Baxalta to break takeover deadlock

    Shire is stepping up pressure on Baxalta to open its books before the UK-listed drugmaker will consider making a higher...

  6. August 13, 2015

    US regional banks benefit in absentia

    Europeans setting out to discover the States head for New York, Boston or San Francisco. But latter-day De Tocquevilles...

  7. August 10, 2015

    Baxalta chief denounces Shire’s ‘lowball’ offer

    Baxalta has doubled down on its opposition to a $30bn hostile takeover approach from Shire, describing the...

  8. August 10, 2015

    Shire gains as biotech bubble fears ease

    Shire was among Monday’s gainers as worries eased that the drugmaker had been caught up in the biotech sector’s mergers...

  9. August 7, 2015

    Acquisitions race could lead to risky buys

    So much for a typically quiet August. Both the City of London and Wall Street were alive with corporate activity this...

  10. August 6, 2015

    Allergan says more acquisitions to come

    Brent Saunders, the frenetic dealmaker who runs Botox-maker Allergan, said there was “certainly more to come” on the...

  11. August 4, 2015

    Shire Pharmaceuticals eyes the big league with Baxalta bid

    When Flemming Ornskov took over as chief executive of Shire in 2013, the UK-listed company was viewed as a midsized...

  12. August 4, 2015

    Shire/Baxalta: merry-go-round

    Would the last American pharma company to leave, please turn out the lights? The next US drugmaker set to decamp to...

  13. August 4, 2015

    CVS Health dips on retail setback

    CVS Health shares weakened on Tuesday after the US drugstore chain warned sales growth in its retail stores had cooled...

  14. August 4, 2015

    Shire in $30bn hostile approach for Baxalta

    Shire is seeking to extend the global wave of dealmaking in the pharmaceuticals sector with a $30bn all-stock hostile...

  15. August 3, 2015

    Shire buys US eyecare business for $300m

    Shire has strengthened its move into eyecare with the $300m acquisition of a US company developing a treatment for...

  16. July 23, 2015

    Shire still on the hunt for acquisitions

    Shire, the UK-listed drugmaker, still sees opportunities for growth-boosting acquisitions despite the surge in...

  17. June 8, 2015

    Shire weighs on FTSE 100 amid bidding war fears

    Shire led the FTSE 100 lower on Monday on fears it could be drawn into a bidding war. The drugmaker dropped 2.8 per...

  18. May 19, 2015

    Circassia £275m fundraising signals revival of UK biotech sector

    When Circassia launched a £275m fundraising last week to finance two acquisitions, the Oxford-based drug developer...

  19. April 30, 2015

    Weak euro lifts European drugmakers

    Sanofi and Bayer reported strong first-quarter results and raised guidance for the full year on Thursday, as drugmakers...

  20. April 10, 2015

    FTSE 100 closes at record high, buoyed by M&A

    The FTSE 100 set a record closing high on Friday, completing a week dominated by a blockbuster deal in the energy...

  21. March 27, 2015

    Shire shines on fourth day of FTSE falls

    Shire was among the outperformers as the FTSE 100 drifted to its fourth straight decline. Drugmaker Shire gained 2.2...

  22. March 26, 2015

    Actavis rewrites ‘big pharma’ playbook

    Move over GlaxoSmithKline. There is a new pharmaceuticals giant in town. After completing its $70bn acquisition of...

  23. March 10, 2015

    Shire shines during sharp FTSE sell-off

    Shire was among the few gainers as the FTSE 100 recorded its sharpest daily fall in five months. Cowen & Co advised...

  24. FT Alphaville

    March 5, 2015

    FirstFT (the new 6am Cut)

    You can sign up to receive the email here. China’s ersatz parliament, the National People’s Congress, kicked off today....

  25. February 25, 2015

    Pharmacyclics considers $19bn sale

    Pharmacyclics is considering a sale that could value the US cancer drugs maker at about $19bn, according to people...

  26. February 22, 2015

    Valeant agrees to buy Salix for $14.5bn

    Valeant, the serial pharmaceuticals dealmaker, has agreed to buy Salix in an all-cash transaction that values the...

  27. February 15, 2015

    Shire has ‘nothing to hide’ on tax, says chief

    Shire’s chief executive has defended the company’s tax arrangements after being identified as one of the beneficiaries...

  28. February 15, 2015

    Monday interview: Flemming Ornskov, Shire CEO

    One evening early last October, Flemming Ornskov, chief executive of Shire, had dinner with the man who was supposed to...

  29. February 12, 2015

    Shire says $1.6bn windfall from AbbVie is tax-free

    Shire has been advised that the $1.6bn “break fee” received from AbbVie after the collapse of their abortive merger is...

  30. February 12, 2015

    Two’s a duopoly, three’s awkward for Kirstie, Phil and Zoopla

    Kirstie Allsopp: Welcome to Disruption, Disruption, Disruption, the property show for estate agents. Phil Spencer:...

  31. February 11, 2015

    M&A helps lift US healthcare stocks

    Gilead Sciences, the biotech behemoth that has seen its market valuation soar to a cool $145bn, has put in a strong...

  32. February 1, 2015

    Shire gets go ahead to market binge-eating medicine

    Shire has received its second important regulatory breakthrough in two weeks after winning US approval for the first...

  33. January 12, 2015

    Shire: details matter

    Announcing its $5.2bn purchase of NPS Pharma, Shire said it “expects that the transaction will deliver return on...

  34. January 12, 2015

    NPS prospects dependent on drug approval

    Shire’s $5.2bn acquisition of NPS Pharmaceuticals on Sunday was the latest example of a larger drugmaker making a big...

  35. January 12, 2015

    Fresh round of M&A sweeps pharma sector

    Another round of mergers and acquisitions is sweeping the pharmaceuticals sector, in a sign that last year’s boom in...

  36. FT Alphaville

    January 12, 2015


    A show of unity in Paris, an AirAsia black box and Apple’s secret door More than 3.7m marched in Paris and across...

  37. FT Alphaville

    January 12, 2015

    FirstFT (the new 6am cut)

    Read the email in full below or sign up to receive it here. More than 3.7m marched in Paris and across France in a...

  38. January 11, 2015

    Shire in $5.2bn deal for US biotech NPS

    Shire, Britain’s third-largest drugmaker by market value, has made its biggest ever acquisition with a $5.2bn deal for...

Search for Shire PLC and


Videos from FT.com that closely match this topic

  1. Lex on why tax inversions are losing their appeal...
    Wed Oct 15 15:22:21 GMT 2014

    Lex on why tax inversions are losing their appeal